Cross-sectional Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Between 18 and 64 Years Old Using the Vaccinees Perception of Injection

CompletedOBSERVATIONAL

Enrollment

447

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

January 4, 2025

Study Completion Date

January 4, 2025

Conditions

Influenza ImmunizationHealth Volunteers

Interventions

BIOLOGICAL

RIV3

intramuscular injection

Trial Locations (1)

Investigational site, Swiftwater

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY